Get the Stockscreener App
3.56
0.28%
-0.010
After Hours:
3.59
0.03
+0.84%
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
Iovance: The Company Makes It Hard To Estimate Revenue Growth (NASDAQ:IOVA) - Seeking Alpha
Philly weekly roundup: Iovance Biotherapeutics expands; Jawnt-SpotHero partnership; Mayor's budget address - Technical.ly
Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) the Most Oversold Penny Stocks to Buy According to Analysts? - Insider Monkey
Stifel maintains Buy on Iovance Biotherapeutics stock, $18 target By Investing.com - Investing.com Canada
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up? - Yahoo
Melanoma Therapeutics Market to Reach $ 8.35 Bn by 2032Key - openPR
Proficio Capital Partners LLC Acquires New Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
SBI Securities Co. Ltd. Acquires New Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today - AOL
Can Amtagvi Drive IOVA's Return To Glory - RTTNews
IOVA stock touches 52-week low at $3.62 amid market challenges - Investing.com
Iovance Biotherapeutics Inc to Host Earnings Call - ACCESS Newswire
Iovance Biotherapeutics (NASDAQ:IOVA) Given New $19.00 Price Target at The Goldman Sachs Group - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 5.8% After Analyst Downgrade - Defense World
Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Dips 27% Despite Reaffirmed 2025 Earnings Guidance - Yahoo Finance
Iovance Biotherapeutics price target lowered to $30 from $34 at Chardan - Yahoo Finance
Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Cut to $19.00 by Analysts at The Goldman Sachs Group - Defense World
Chardan Cuts Price Target on Iovance Biotherapeutics to $30 From $34, Keeps Buy Rating - Marketscreener.com
Rhumbline Advisers Has $2.86 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Iovance Biotherapeutics’ (IOVA) “Buy” Rating Reiterated at HC Wainwright - Defense World
Research Analysts Set Expectations for IOVA Q1 Earnings - Defense World
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported Earnings, And Analysts Cut Their Target Price - Simply Wall St
Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 12-Month Low After Analyst Downgrade - Defense World
Iovance Biotherapeutics (NASDAQ:IOVA) Given "Buy" Rating at HC Wainwright - MarketBeat
Iovance Biotherapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance UK
Robert W. Baird Cuts Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $20.00 - MarketBeat
Iovance Biotherapeutics Target of Unusually Large Options Trading (NASDAQ:IOVA) - Defense World
Iovance Biotherapeutics (NASDAQ:IOVA) Releases Earnings Results, Hits Expectations - MarketBeat
Iovance Biotherapeutics’ Earnings Call Highlights Growth and Challenges - TipRanks
Iovance Biotherapeutics (NASDAQ:IOVA) Announces Quarterly Earnings Results, Meets Estimates - MarketBeat
New York State Common Retirement Fund Sells 98,840 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Forecasting The Future: 4 Analyst Projections For Iovance Biotherapeutics - Benzinga
Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade) - Seeking Alpha
Truist Adjusts Price Target on Iovance Biotherapeutics to $15 From $25, Maintains Buy Rating - Marketscreener.com
IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty - Yahoo Finance
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2024 Earnings Call Transcript - Insider Monkey
Iovance Biotherapeutics Q4 Loss Narrows, Revenue Rises -February 28, 2025 at 03:51 am EST - Marketscreener.com
Iovance Biotherapeutics Inc (IOVA) Q4 2024 Earnings Call Highlights: Strong Revenue and ... - Yahoo Finance
Iovance Biotherapeutics: Q4 Earnings Snapshot - The Washington Post
Iovance Biotherapeutics Reports Strong 2024 Earnings - TipRanks
Earnings call transcript: Iovance Biotherapeutics Q4 2024 results miss revenue forecasts - Investing.com India
Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Iovance Biotherapeutics reports Q4 EPS (26c), consensus (27c) - TipRanks
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Iovance Biotherapeutics (IOVA) Projected to Post Earnings on Thursday - MarketBeat
Iovance down 18% warning it could be impacted by geopolitical instability, inflation - MSN
IOVANCE BIOTHERAPEUTICS, INC. SEC 10-K Report - TradingView
Iovance Biotherapeutics misses Q4 revenue estimates, shares drop - Investing.com
Iovance Biotherapeutics misses Q4 revenue estimates, shares drop By Investing.com - Investing.com Australia
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and - The Bakersfield Californian
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024 - GlobeNewswire
Iovance Biotherapeutics options imply 12.4% move in share price post-earnings - TipRanks
Iovance Biotherapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $21.07 Average PT from Brokerages - MarketBeat
Hussman Strategic Advisors Inc. Has $622,000 Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):